COMMITTEE

CHAIR PERSONS
Stefan Vieths  Langen, Germany
Vera Mahler  Langen, Germany

SCIENTIFIC COMMITTEE
C. Akdis  Davos, Switzerland
B. Bohle  Vienna, Austria
K.-H. Buchheit  Strasbourg, France
T. B. Casale  Tampa, FL, USA
M. Chapman  Charlottesville, VA, USA
F. de Blay  Strasbourg, France
I. Eichler  London, United Kingdom
A. Frew  Brighton, United Kingdom
T. Higenbottam  Worthing, United Kingdom
M. Hoefnagel  Utrecht, The Netherlands
H. Jacobi  Hørsholm, Denmark
M. Jutel  Wroclaw, Poland
J. Kleine-Tebbe  Berlin, Germany
M. Larché  Hamilton, ON, Canada
P. Moingeon  Antony, France
O. Pfaar  Wiesbaden, Germany
C. Pini  Rome, Italy
L. Poulsen  Hellerup, Denmark
R. L. Rabin  Silver Spring, MD, USA
J. E. Slater  Silver Spring, MD, USA
M. Timon  Madrid, Spain
R. G. van Wijk  Rotterdam, The Netherlands
T. Werfel  Hannover, Germany
C. Willers  Reinbek, Germany

LOCAL ORGANIZING COMMITTEE
Stefan Vieths & Vera Mahler, Chair Persons;
Regina Gutberlet, Seminar Secretary;
Birgit Ahrens, Detlef Bartel, Andreas Bonertz,
Thomas Holzhauser, Susanne Kaul, Stephan Scheurer,
Frank Schuler, Lothar Vogel

SEMINAR SECRETARY
Regina Gutberlet
Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59
63225 Langen, Germany
Phone  +49 6103 77 60 01
Mobile  +49 177 266 39 25
Email  PEI-Seminar@pei.de
GENERAL INFORMATION

REGISTRATION AND INFORMATION DESK

OPENING HOURS
September 6, 2017 11:00 – 18:00
September 7, 2017 08:00 – 19:00
September 8, 2017 08:00 – 17:45
September 9, 2017 08:00 – 15:00

PRESENTATION MEDIA

Please bring your presentation files to the Conference Office before the morning or afternoon session, at latest. You may also send your data via e-mail to: PEI-Seminar@pei.de

PRELIMINARY SOCIAL PROGRAMME

WEDNESDAY SEPTEMBER 6, 2017
19:30
Opening and Welcome Reception with Dinner at Maritim Hotel, Bad Homburg

THURSDAY, SEPTEMBER 7, 2017
18.30 Leisure Time
Suggestions will be offered by our staff on request

FRIDAY, SEPTEMBER 8, 2017
18:45
Social Event at Alter Güterbahnhof, Bad Homburg
WEDNESDAY, SEPTEMBER 6, 2017

13:00 – 15:00

Expert Session on Regulatory Requirements for Mass Spectrometric Data (Pre-registration required)
Chair: Andreas Reuter, Langen, Germany; tba

- Andreas Reuter - Quality Control and Standardization of Allergen Products with Mass Spectrometry. Introductory lecture.
- Jay Slater - Standardization of Allergen Products with Mass Spectrometry in the USA
- Henrik Næsted - Quality Control of Complex Allergen Products
- Martin Himly - Quality Control of Purified Allergens. Detailed Mass Spectrometric Characterization of Recombinant Allergens as Reference Preparations

parallel: 13:00 – 15:00

IUIS Allergen Standardization SubCommittee
Chair: Stefan Vieths, Langen, Germany; tba

15:00 – 15:30 Coffee Break

15:30 – 17:45

ALLERGY DIAGNOSTICS

Opening Lecture:
In Vivo Diagnostics for Type I and Type IV Allergies – Current Status and Unmet Needs
Vera Mahler, Langen, Germany

State of the Art and New Developments of Haptens for Diagnosis of Type IV Allergies
Wolfgang Uter, Erlangen, Germany

Future Availability of Test Allergens – A Manufacturer’s Perspective
Michael Bauer, Reinbek, Germany

How to Authorize New in vivo Test Allergens?
Susanne Kaul, Langen, Germany
In vivo Versus in vitro Testing (EAACI Position)
Lars K. Poulsen, Copenhagen, Denmark

Relevance of Component Resolved Testing for AIT – Current Evidence
Giovanni Passalacqua, Genova, Italy

General Discussion

17:45–18:15
Opening Lecture: History and Future of Allergen Standardization
Thomas A. Platts-Mills, Charlottesville, USA

From 19:30 Opening and Welcome Reception with Dinner
THURSDAY, SEPTEMBER 7, 2017

09:00 – 12:00

REGULATION OF ALLERGEN PRODUCTS – STATE OF THE ART AND NEW DEVELOPMENTS

Welcome Address
Stefan Vieths and Vera Mahler, Langen, Germany

Regulatory Tools for Accelerated Market Access of Biomedicines
Hans-Georg Eichler, London, United Kingdom

EAACI Regulatory Task Force Paper
Andreas Bonertz, Langen, Germany

Regulation of Allergen Products in the US – Current Status and Future Developments
Jay Slater, Silver Spring, USA

State of the Art and Recent Developments of Allergen Regulation in France
Frédéric de Blay, Strasbourg, France

Update on the TAV Process in Germany
Stefan Vieths, Langen, Germany

Coffee Break (10:50 – 11:10)

Recent Regulatory Developments at EMA and HMA Level
Marcel Hoefnagel, Utrecht, The Netherlands

Experience of a European Allergen Manufacturer in China
Anne Lützhøft, Hørsholm, Denmark

General Discussion
12:00 – 16:30
CHARACTERIZATION AND CONTROL OF ALLERGEN PRODUCTS

Process and Requirements for Revision of Ph.Eur. Monographs
Karl-Heinz Buchheit, Strasbourg, France

Physicochemical and Immunological Characterization of Grass Allergoids
Matthew Heath, Worthing, United Kingdom

The Use of Allergen-Specific Monoclonal Antibodies for the Detection of Relevant Allergens in Mite Allergoids
Gerald Reese, Reinbek, Germany

Lunch (13:00 – 14:00)

Biological Standardization of Allergen Products – An Outdated Requirement?
Jörg Kleine-Tebbe, Berlin, Germany

Allergenic Products Testing in the USA
Ronald Rabin, Silver Spring, USA

General Discussion

Mass Spectrometry vs ELISA in Allergen Product Quality Control
Julia Zimmer & Andreas Reuter, Langen, Germany

Pro and Con Discussion: Mass Spectrometry vs ELISA in Allergen Product Quality Control
• Martin Chapman, Charlottesville, USA
• Julia Zimmer & Andreas Reuter, Langen, Germany
• Philippe Moingeon, Paris, France
Moderator: Jonas Lidholm, Uppsala, Sweden

16:30 – 16:50 Coffee Break
16:50 – 18:30

ENDPOINTS AND BIOMARKERS OF ALLERGEN IMMUNOTHERAPY

EAACI Task Force Paper on Biomarkers
Mohamed Shamji, London, United Kingdom

The Potential of Metabolomics for Developing AIT Biomarkers
Domingo Barber, Madrid, Spain

Validation of Endpoints of AIT Trials in Allergic Rhinitis
Moisés Calderón, London, United Kingdom

Endpoints of AIT Trials in Asthma
J. Christian Virchow, Rostock, Germany

General Discussion
08:30 – 10:30

RECENT DEVELOPMENTS OF ALLERGEN IMMUNOTHERAPY IN CHILDREN

Current Status of Pediatric Studies According to the Standard PIP
Irmgard Eichler, London, United Kingdom

Allergen Exposure Chambers for the Development of AIT Products in Children?
Petra Zieglmayer, Vienna, Austria

To what Extent is Extrapolation from Adult Results to Children Possible?
Hugo Tavares, Espinho, Portugal

Implications from the GAP Study for Future Pediatric Developments
Henrik Jacobi, Hørsholm, Denmark

Minimum Requirements for a limited Pediatric Development of AIT Products
Matthias Kopp, Lübeck, Germany

General Discussion

10:30 – 10:50  Coffee Break

10:50 – 13:00

IMMUNOTHERAPY OF FOOD ALLERGY

Comparison of SLIT and OIT in Peanut Allergy
Kari Nadeau, Stanford, USA

OIT in Milk and Egg Allergy
Kirsten Beyer, Berlin, Germany

Hypoallergens for SCIT Treatment of Fish and Peanut Allergy
Ronald van Ree, Amsterdam, The Netherlands
Epicutaneous AIT of Food Allergy  
Hugh Sampson, New York, USA

Threshold Dose Determination in Food Allergy and its Relevance for Daily Life  
Anthony Dubois, Groningen, The Netherlands

General Discussion

13:00 – 14:00  Lunch

14:00 – 15:30  
NOVEL FORMS OF ALLERGEN IMMUNOTHERAPY

New Insights in AIT Mechanisms  
Cezmi A. Akdis, Davos, Switzerland

Novel Vaccines Targeting Dendritic Cells by Coupling Allergoids to Mannan  
Oscar Palomares, Madrid, Spain

Recombinant Allergens for the Treatment of Pollen-Related Food Allergy  
Barbara Bohle, Vienna, Austria

Intralymphatic IMAT Approach in Veterinary Medicine  
Horst Rose, Ingelheim, Germany

General Discussion

15:30 – 16:00  Coffee Break

16:00 – 17:30  
CRITICAL FACTORS OF CLINICAL TRIALS IN ALLERGEN IMMUNOTHERAPY

Placebo Effect in AIT Trials  
Anthony Frew, Brighton, United Kingdom

Lessons Learned from the Peptide Approach  
Mark Larché, Hamilton, Canada
Positive and Negative AIT Trials. What Makes the Difference?
Roy Gerth van Wijk, Rotterdam, The Netherlands

Defining Pollen Season including Pollen Concentrations for Clinical Trials of Allergen Immunotherapy
Oliver Pfaar, Wiesbaden, Germany

General Discussion

From 18:45
Social Event: Alter Güterbahnhof Bad Homburg
SATURDAY, SEPTEMBER 9, 2017

09:00 – 10:15

CHALLENGE TESTS FOR EFFICACY ASSESSMENT

Standardized Production and Characterization of Food Challenge Meals
Clare Mills, Manchester, United Kingdom

Clinical Validation of AECs for Phase III AIT Trials
Torsten Sehlinger, Berlin, Germany

Nasal and Conjunctival Provocation Tests – Suitable Tools in Dose Finding Studies
Tim Higenbottam, Worthing, United Kingdom

General Discussion

10:15 – 10:30 Coffee Break

10:30 – 11:30

BIOLOGICS FOR THE TREATMENT OF ALLERGY AND ASTHMA

Monoclonal Antibodies for the Treatment of Atopic Dermatitis
Thomas Werfel, Hannover, Germany

Biologics for Asthma Treatment and Corresponding Biomarkers and Endotypes
Thomas B. Casale, Tampa, USA

General Discussion
11:30 – 13:00

PREVENTION OF ALLERGY BY IMMUNOMODULATION AND ALLERGEN IMMUNOTHERAPY

Lessons Learned from the Pilot Prophylactic SLIT Study in High Risk Children
Graham Roberts, Southampton, United Kingdom

Interplay between a Microbiota and Immune System: A Role for Probiotics?
Liam O’Mahony, Davos, Switzerland

EAACI Systematic Review on Allergy Prevention
Antonella Muraro, Padua, Italy

General Discussion

Farewell – Closing Remarks
Stefan Vieths, Vera Mahler, Langen, Germany

From 13:00 Lunch
SEMINAR VENUE

MARITIM HOTEL BAD HOMBURG
Ludwigstraße 3
61348 Bad Homburg v. d. H., Germany
Telefon +49 (0) 6172 660-0
Fax +49 (0) 6172 660-100

TRAVEL INFORMATION
>> from Frankfurt International Airport
(25 km by taxi appr. € 50)
S-train S8/S9 to Frankfurt Main Station
>> from Frankfurt Main Station
S-train S5 to Bad Homburg leaves from gate 104 every 15 minutes
The Organizing Committee would like to thank the following institutions and organizations for their generous support:

BMG – Bundesministerium für Gesundheit
FDA – U.S. Food and Drug Administration